IsomAb Ltd, a UK-based biotechnology company developing novel isoform-specific disease modifying antibody treatments, for peripheral arterial disease and other ischaemic conditions, has appointed Dr. Gary Burgess as Chief Medical Officer (CMO).

Burgess has over two decades of experience spanning all phases of drug development, from Phase 1 to Phase 4, in a diverse range of diseases and therapeutic areas. Throughout this journey, he has maintained close collaboration with regulatory agencies, including the FDA, EMA, and PMDA.

Having held senior positions at Pfizer, Aerami Therapeutics, Vectura Ltd and Conatus Pharmaceuticals, Burgess has gained recognition as an international expert in Metabolic Associated Steatohepatitis (MASH, formerly NASH) and pulmonary hypertension. Whilst at Pfizer he also worked in the Cardiovascular Therapeutic Area on treatments for vascular diseases. 

Burgess completed his undergraduate and postgraduate medical training at the University of Stellenbosch.